Scientists seek best dose of Last-Resort antibiotics for superbug infections
NCT ID NCT06717594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study is looking at how two antibiotics, ceftazidime/avibactam and fosfomycin, work in the body to treat infections caused by carbapenem-resistant Enterobacterales (CRE), a type of superbug. Researchers will monitor 60 adult patients to see if the drug levels in their blood reach targets that effectively kill the bacteria. The goal is to find the right dosing to improve treatment for these difficult infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ceftazidime/avibactam and fosfomycin
What this could lead to
If successful, this study could help doctors determine the most effective dosing of these antibiotics for treating hard-to-kill CRE infections.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. The small size (60 participants) and focus on specific bacteria may limit how widely the results apply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAM NEGATIVE INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITINGBologna, Bologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Biomedicina de Sevilla (IBiS), Hospital Virgen Macarena/CSIC/Universidad de Sevilla
RECRUITINGSeville, Seville, 41013, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••